{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T12:04:57Z","timestamp":1768910697054,"version":"3.49.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Research Project on High-Quality Development of Hospital Pharmacy","award":["NIHAYS2403"],"award-info":[{"award-number":["NIHAYS2403"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Voriconazole is widely used for invasive fungal infections in critically ill patients, but its pharmacokinetics may be significantly altered by extracorporeal membrane oxygenation (ECMO). Data on the impact of different ECMO modes are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective observational study including all patients admitted to the ICU from January 2018 to May 2025 who were treated with voriconazole for suspected fungal infections. Voriconazole trough concentrations (Cmin) were compared between ECMO and non-ECMO patients. Multivariate linear regression was used to identify clinical predictors of Cmin, and subgroup analyses were performed by ECMO mode and other relevant covariates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 166 patients (492 samples) were included, including 33 ECMO patients (111 samples) and 133 non-ECMO patients (381 samples). There was no significant difference in voriconazole trough concentrations between the ECMO and non-ECMO groups. When stratified by mode, VAV-ECMO was associated with significantly lower concentrations than non-ECMO (P\u200a=\u200a0.004), whereas VV- and VA-ECMO were comparable to non-ECMO. In multivariate linear regression, increasing age and coadministration with amiodarone were associated with higher voriconazole Cmin, whereas lower albumin levels and concomitant CRRT were associated with reduced concentrations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ECMO support did not significantly reduce voriconazole Cmin compared with the non-ECMO group. However, VAV-ECMO is associated with reduced voriconazole exposure, suggesting a configuration-specific rather than uniform ECMO effect. Routine therapeutic drug monitoring remains essential.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf501","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T13:03:11Z","timestamp":1766581391000},"source":"Crossref","is-referenced-by-count":0,"title":["Impact of extracorporeal membrane oxygenation modes on voriconazole exposure in critically ill patients"],"prefix":"10.1093","volume":"81","author":[{"given":"Xinrui","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Beijing Chaoyang Hospital, Capital Medical University , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Capital Medical University , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyu","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Chaoyang Hospital, Capital Medical University , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine, Beijing Chaoyang Hospital, Capital Medical University , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Anzhen Hospital, Capital Medical University , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine, Beijing Chaoyang Hospital, Capital Medical University , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoling","family":"An","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Chaoyang Hospital, Capital Medical University , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"2026011902083629000_dkaf501-B1","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s40262-023-01264-0","article-title":"Antifungal dosing in critically ill patients on extracorporeal membrane oxygenation","volume":"62","author":"Lyster","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"2026011902083629000_dkaf501-B2","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/MAT.0000000000000489","article-title":"Investigation of key circuit constituents affecting drug sequestration during extracorporeal membrane oxygenation treatment","volume":"63","author":"Park","year":"2017","journal-title":"ASAIO J"},{"key":"2026011902083629000_dkaf501-B3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/MAT.0000000000001802","article-title":"Variable sequestration of antifungals in an extracorporeal membrane oxygenation circuit","volume":"69","author":"Lyster","year":"2023","journal-title":"ASAIO J"},{"key":"2026011902083629000_dkaf501-B4","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1007\/s00134-007-0606-2","article-title":"Potential drug sequestration during extracorporeal membrane oxygenation: results from an ex vivo experiment","volume":"33","author":"Mehta","year":"2007","journal-title":"Intensive Care Med"},{"key":"2026011902083629000_dkaf501-B5","doi-asserted-by":"publisher","first-page":"106692","DOI":"10.1016\/j.ijantimicag.2022.106692","article-title":"Voriconazole therapeutic drug monitoring and hepatotoxicity in critically ill patients: a nationwide multi-centre retrospective study","volume":"60","author":"Wang","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"2026011902083629000_dkaf501-B6","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s40262-016-0416-1","article-title":"Dose-dependent bioavailability and CYP3A inhibition contribute to non-linear pharmacokinetics of voriconazole","volume":"55","author":"Hohmann","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"2026011902083629000_dkaf501-B7","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1177\/08971900211060959","article-title":"Fluctuating voriconazole concentrations during extracorporeal membrane oxygenation","volume":"36","author":"Vu","year":"2023","journal-title":"J Pharm Pract"},{"key":"2026011902083629000_dkaf501-B8","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.3390\/antibiotics12071100","article-title":"Voriconazole pharmacokinetics in critically ill patients and extracorporeal membrane oxygenation support: a retrospective comparative case-control study","volume":"12","author":"Ronda","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"2026011902083629000_dkaf501-B9","doi-asserted-by":"publisher","first-page":"dlae045","DOI":"10.1093\/jacamr\/dlae045","article-title":"Factors influencing voriconazole plasma level in intensive care patients","volume":"6","author":"Hinze","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"2026011902083629000_dkaf501-B10","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.3390\/microorganisms9071543","article-title":"A large retrospective assessment of voriconazole exposure in patients treated with extracorporeal membrane oxygenation","volume":"9","author":"Van Daele","year":"2021","journal-title":"Microorganisms"},{"key":"2026011902083629000_dkaf501-B11","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s00134-010-2041-z","article-title":"Determinants of drug absorption in different ECMO circuits","volume":"36","author":"Wildschut","year":"2010","journal-title":"Intensive Care Med"},{"key":"2026011902083629000_dkaf501-B12","doi-asserted-by":"publisher","first-page":"972585","DOI":"10.3389\/fphar.2022.972585","article-title":"Impact of extracorporeal membrane oxygenation on voriconazole plasma concentrations: a retrospective study","volume":"13","author":"Ye","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026011902083629000_dkaf501-B13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1590\/s1806-37562016000000299","article-title":"Extracorporeal respiratory support in adult patients","volume":"43","author":"Romano","year":"2017","journal-title":"J Bras Pneumol"},{"key":"2026011902083629000_dkaf501-B14","doi-asserted-by":"publisher","first-page":"1126580","DOI":"10.3389\/fphar.2023.1126580","article-title":"Factors influencing plasma concentration of voriconazole and voriconazole-N-oxide in younger adult and elderly patients","volume":"14","author":"Cheng","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026011902083629000_dkaf501-B15","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s10096-005-1325-7","article-title":"Plasma levels of voriconazole administered via a nasogastric tube to critically ill patients","volume":"24","author":"Mohammedi","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026011902083629000_dkaf501-B16","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/jac\/dkp026","article-title":"Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation","volume":"63","author":"Spriet","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2026011902083629000_dkaf501-B17","doi-asserted-by":"publisher","first-page":"e13545","DOI":"10.1111\/tid.13545","article-title":"Decreasing voriconazole requirement in a patient after extracorporeal membrane oxygenation discontinuation: a case report","volume":"23","author":"Peterson","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"2026011902083629000_dkaf501-B18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1093\/jac\/dky392","article-title":"Real-world implications of QT prolongation in patients receiving voriconazole and amiodarone","volume":"74","author":"Mourad","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026011902083629000_dkaf501-B19","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1128\/AAC.00626-12","article-title":"Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011902083629000_dkaf501-B20","doi-asserted-by":"publisher","first-page":"666296","DOI":"10.3389\/fphar.2021.666296","article-title":"Interactive effects of glucocorticoids and cytochrome P450 polymorphisms on the plasma trough concentrations of voriconazole","volume":"12","author":"Jia","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026011902083629000_dkaf501-B21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ijantimicag.2016.11.025","article-title":"Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole","volume":"49","author":"Qi","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2026011902083629000_dkaf501-B22","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1111\/bcp.14267","article-title":"A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations","volume":"86","author":"Blanco Dorado","year":"2020","journal-title":"Br J Clin Pharmacol"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/2\/dkaf501\/66444079\/dkaf501.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/2\/dkaf501\/66444079\/dkaf501.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T07:08:46Z","timestamp":1768806526000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkaf501\/8429085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,19]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf501","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,19]]},"article-number":"dkaf501"}}